{
  "ticker": "CHM",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971721",
  "id": "02971721",
  "pages": 11,
  "price_sensitive": false,
  "date": "20250723",
  "time": "0845",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250723/pdf/06m1n8l91l4pnt.pdf",
  "summary": "### **Summary of Material Information:**  \n- **Clinical Trial Updates:**  \n  - **CHM CDH17 CAR-T (Dose Level 1):**  \n    - Stable disease in 2/4 patients (one CRC patient at day 150, one NET patient until day 150).  \n    - Progressive disease in 2/4 patients.  \n  - **CHM CDH17 CAR-T (Dose Level 2):**  \n    - One patient (CRC) passed DLT (Dose-Limiting Toxicity) assessment; pending day 28 scan.  \n    - Two additional NET patients manufactured for treatment.  \n  - **CHM CORE-NK (AML Trial):**  \n    - 2/3 patients achieved Complete Response with incomplete blood recovery (CRi).  \n    - No dose-limiting toxicities, cytokine release syndrome, or GvHD observed.  \n\n- **Capital & Corporate:**  \n  - **$16.6m raised**, including $5.6m from a US Family Office.  \n  - **Lind facility repaid** in full by July 2025.  \n  - **Cost reductions implemented**, including headcount cuts.  \n\n- **Operational Highlights:**  \n  - **8/8 successful GMP manufacturing runs** completed.  \n  - **Four active clinical trials** across CHM CDH17, CORE-NK, and CLTX platforms.  \n\nNo material information omitted due to boilerplate/disclaimers.",
  "usage": {
    "prompt_tokens": 1515,
    "completion_tokens": 305,
    "total_tokens": 1820,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-22T22:57:07.570473"
}